Fri, September 20, 2024
AUS Edition NZ Edition UK Edition CA Edition USA Edition FRA Edition GER Edition ESP Edition ITA Edition NLD Edition
PRT Edition SWE Edition GRC Edition IND Edition POL Edition BRA Edition ZAF Edition RUS Edition CHN Edition UAE Edition
Kalkine Media ASX Share Market News & Research
Kalkine Media ASX Share Market News & Research
  1. Home
  2. Companies
  3. DXB
Healthcare
Facebook Twitter Linkedin

Dimerix Ltd (ASX:DXB)

0.38 AUD

0.000 0.000%
Last Updated at: 2024-09-19T06:10:00Z

Dimerix Ltd

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 which is in phase 2 clinical trial for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. Dimerix Limited is headquartered in Fitzroy, Australia.

425 Smith Street, Fitzroy, VIC, Australia, 3065

1300 813 321

https://dimerix.com

Key Executives

Sr. No. Name Title Year Born
1. Dr. Nina Webster B.Sc., M.B.A., M.IP.Law, MBA, Ph.D. CEO, MD & Director NA
2. Dr. Ashish Soman M.B.A., M.D., MBBS Chief Medical Officer NA
3. Mr. Hamish George B.Com., C.A. CFO & Company Sec. NA
4. Mr. Kevin Donald George Pfleger BA (Hons), MA, Ph.D. Chief Scientific Advisor NA
5. Ms. Elizabeth McCall B.Com(Hons), B.Juris, BJURIS, GAICD, L.L.B., LLB. Bus. Devel. Officer NA
6. Mr. Hamish George B.Com., C.A. CFO & Company Secretary NA
7. Dr. David Everett Fuller BPharm, M.D., MBBS Chief Medical Officer 1964
8. Mr. Robert Shepherd Chief Commercialisation Officer NA
9. Mr. Hamish George B.Com., C.A. CFO & Company Secretary NA
10. Dr. David Everett Fuller BPharm, M.D., MBBS Chief Medical Officer 1964

Peers

Sector: Healthcare

Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE(x) Forward PE(x) Price Sales TTM(x) Price to Book Value(x) Enterprise Value to Revenue(x) Enterprise Value to EBITDA(x)
CSL

CSL Ltd

 -0.920 0.311% 299 41.150 31.348 9.601 5.157 10.914 34.928
TLX

Telix Pharmaceuticals Ltd

 +0.910 5.098% 17.88 983.000 21.008 8.466 28.693 8.215 177.654
CU6

Clarity Pharmaceuticals Ltd

 +0.050 0.654% 7.67 0.000 0.000 204.165 15.907 0.000 -0.779
NEU

Neuren Pharmaceuticals Ltd

 +0.160 1.196% 13.5 14.320 15.152 9.149 5.266 6.689 8.718

Income Statement

(Currency in AUD)
Breakdown 30-06-2023 30-06-2022 30-06-2021 30-06-2020 30-06-2019
Income Before Tax -13.803M -10.491M -6.372M -4.494M -2.886M
Minority Interest - - - - -
Net Income -13.803M -10.493M -6.37M -4.491M -1.434M
Selling General Administrative 2.168M 2.389M 1.442M 1.3M 1.459M
Gross Profit 8.984M - - - 1.447M
Reconciled Depreciation 0.056M 0.051M 0.045M 0.014M 0.005M
Ebit -22.823M -16.956M -10.928M -6.918M -4.338M
Ebitda -22.767M -16.906M -10.884M -6.905M -4.334M
Depreciation And Amortization 0.056M 0.051M 0.045M 0.014M 0.005M
Operating Income -13.84M -16.956M -10.928M -6.918M -4.338M
Other Operating Expenses 22.823M 16.956M 10.928M 6.918M 4.338M
Interest Expense - 0.002M 0M 0M 0M
Tax Provision 0M 0M 0M 0M 0M
Interest Income 0.037M 0.002M 0.002M 0.003M 0.018M
Net Interest Income 0.037M 0.002M 0.002M 0.003M 0.018M
Income Tax Expense -0.037M 0.002M -0.002M -0.003M -1.452M
Total Revenue 8.984M 0.002M 0.002M 0.003M 0.018M
Total Operating Expenses 22.823M 16.956M 10.928M 6.918M 4.338M
Cost Of Revenue - - - - -
Total Other Income Expense Net 8.984M 6.466M 4.556M 2.424M 1.452M
Net Income From Continuing Ops -13.803M -10.491M -6.372M -4.494M -2.886M
Net Income Applicable To Common Shares -13.803M -10.491M -6.372M -4.494M -2.886M

Balance Sheet

(Currency in AUD)
Breakdown 30-06-2024 30-06-2023 30-06-2022 30-06-2021 30-06-2020
Total Assets 32.079M 17.758M 16.497M 9.421M 10.389M
Intangible Assets - - - - -
Other Current Assets 0.258M 0.021M 0.073M 0.043M 0.03M
Total Liab 13.893M 11.794M 2.074M 7.952M 2.63M
Total Stockholder Equity 18.186M 5.963M 14.423M 1.468M 7.759M
Other Current Liab 2.403M 6.619M 0.913M 5.432M 1.481M
Common Stock 83.378M 55.489M 50.895M 28.389M 28.344M
Capital Stock 83.378M 55.489M 50.895M 28.389M 28.344M
Retained Earnings -69.176M -52.101M -38.298M -27.808M -21.436M
Good Will - - - - -
Other Assets - - - - -
Cash 22.141M 7.992M 9.63M 5.25M 7.786M
Cash And Equivalents - 7.992M 9.63M 5.25M 7.786M
Total Current Liabilities 3.364M 11.756M 2.024M 7.952M 2.63M
Current Deferred Revenue 0.575M -5.958M -0.052M -5.093M -1.094M
Net Debt -21.992M -2.034M -9.557M -0.157M -6.691M
Short Term Debt 0.08M 5.958M 0.052M 5.093M 1.094M
Short Long Term Debt - 5.936M - 5.05M 1.063M
Short Long Term Debt Total 0.15M 5.958M 0.073M 5.093M 1.094M
Other Stockholder Equity - -3.388M -12.597M -0.582M -6.908M
Property Plant Equipment - 0.006M 0.009M 0.001M 0.001M
Total Current Assets 31.916M 17.751M 16.488M 9.419M 10.388M
Long Term Investments - - - - -
Short Term Investments - - - - -
Net Receivables 9.517M 9.554M 6.385M 4.008M 2.464M
Long Term Debt - - - - -
Inventory - 0.184M 0.401M 0.119M 0.108M
Accounts Payable 0.305M 5.137M 1.111M 2.52M 1.149M
Accumulated Other Comprehensive Income 3.984M 2.575M 1.826M 0.887M 0.851M
Non Currrent Assets Other - -0.006M -0.009M -0.001M -0.001M
Non Current Assets Total 0.162M 0.006M 0.009M 0.001M 0.001M
Capital Lease Obligations 0.15M 0.022M 0.073M 0.043M 0.031M
Long Term Debt Total - 0M 0.021M 0M 0M

Cash Flow

(Currency in AUD)
Breakdown 30-06-2023 30-06-2022 30-06-2021 30-06-2020 30-06-2019
Investments -0.002M -0.011M 0.004M - -0.007M
Total Cashflows From Investing Activities -0.002M -0.011M 0.004M 0.004M -0.007M
Total Cash From Financing Activities 11.069M 17.691M 3.825M 8.911M 8.911M
Net Income -13.803M -10.491M -6.372M -4.494M -1.434M
Change In Cash -1.638M 4.38M -2.536M 4.222M -2.721M
Begin Period Cash Flow 9.63M 5.25M 7.786M 3.563M 6.284M
End Period Cash Flow 7.992M 9.63M 5.25M 7.786M 3.563M
Total Cash From Operating Activities -12.729M -13.436M -6.36M -4.721M -11.662M
Depreciation 0.056M 0.051M 0.045M 0.014M 0.005M
Other Cashflows From Investing Activities - 0M 0.014M - -
Dividends Paid - 0.001M 1.24M 1.073M -
Change To Inventory - - - - -
Sale Purchase Of Stock -0.445M -1.24M -1.24M -0.441M -0.441M
Other Cashflows From Financing Activities 2.789M -0.047M 4.853M 1.012M 1.012M
Capital Expenditures 0.002M 0.011M 0.01M 0.01M 0.007M
Change In Working Capital -3.168M -2.337M -1.544M -1.189M 1.092M
Other Non Cash Items 1.018M -2.996M -0.033M -0.241M 2.882M
Free Cash Flow -12.731M -13.447M -6.37M -4.721M -11.669M

No data found

Disclaimer

Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Related Articles

Code Price Chg %Chg
View All
Code Price Chg %Chg
View All
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Open in the App